WHIM Syndrome Overview
Philip M. Murphy, MD, Chief, Molecular Signaling Section, Laboratory of Molecular Immunology; Chief, Laboratory of Molecular Immunology, National Institute of Allergy and Infection, provides an overview of WHIM syndrome.
PATHOPHYSIOLOGY AND EPIDEMIOLOGY
In 2012, French researchers estimated the incidence of WHIM to be less than one in a million births. In a 2019 publication, Italian researchers stated, “The increasing number of patients diagnosed in recent years suggests that the real incidence of this primary immunodeficiency may be underestimated, as delay in its recognition remains remarkable.”
Patients with WHIM syndrome have been reported in the literature at increasing rates over the last decade. A recent publication from the National Institutes of Health (NIH) reported on 105 published cases of WHIM syndrome from 1964-2019. The great majority of cases reported were from the US and Western Europe, especially Italy and France, but cases have also been reported in South America and Asia.
Like many rare diseases, the true prevalence of WHIM syndrome remains unknown, but advances in genetic diagnostic techniques (such as Next-Generation-Sequencing) and rising awareness about the disease is expected to facilitate early recognition and diagnosis.
SIGNS AND SYMPTOMS
The first clinical symptoms, that often appear in very young patients, are recurrent bacterial infections (especially respiratory infections like sinusitis, otitis media, and pneumonia) and cellulitis. More than half of the patients will report a history of treatment resistant warts, which classically appear before the age of 10 years. Warts may be extensive and involve the ano-genital area and related to human papillomavirus virus (HPV) infection (which often first manifests in early childhood between the ages of 5 and 10). These HPV-related warts are resistant to treatments such as freezing (cryotherapy), salicylic acid or even surgical removal that are typically effective in other patients with warts.
In addition to infections and warts, WHIM patients may be prone to an increased risk of cancer (carcinoma), particularly when HPV warts are located in the ano-genital region although there have been reports of cancers in other parts of the body such as oral cavity. The 2019, “Long Term outcome of WHIM syndrome in 18 patients” observed HPV-related malignancy in 17% of patients (3/18). Finally, some patients also have defects of the cardiovascular (in particular Tetralogy of Fallot), urogenital, and nervous systems.
In one review of reported cases, the clinical features of WHIM were noticeable at a mean of 2 years of age, but diagnosis was not made until the patients were 12 or 13 years old. Severe bacterial infection occurred in 78% of patients, with recurrent pneumonia in 61% of cases that was complicated with bronchiectasis in 27% of patients. Patients were a mean age of 11 years of age by the time cutaneous warts were observed (in 61% of children).
While identification of the most notable signs of WHIM syndrome may be straightforward, diagnosis is challenging because of its rarity and the array of the clinical presentation. Complete blood count testing (with differential) will often yield abnormally low neutrophil counts (unless bolstered during episodes of infection), low total white blood cells and low lymphocytes, and about half of the patients have low IgG, IgM and/or IgA concentrations. A detailed patient history often reveals recurrent infections in the patient. However, one of the challenges to diagnosis is the temporary, normal levels of white blood cells during acute infections,[4,6.7] which is the moment when patients most commonly seek medical attention. Because of this, looking only at blood counts drawn during an acute infection can lead clinicians into missing the key sign of low neutrophils, and therefore may cause them to miss the diagnosis. As a result, diagnosis may be delayed until other characteristics of WHIM appear, and this delay may impact the initiation of appropriate treatment.
If WHIM syndrome is suspected, a patient’s diagnosis can be confirmed through genetic tests to identify mutations in the CXCR4 gene. Bone marrow biopsies, If performed, will reveal myelokathexis.
MANAGEMENT AND CURRENT TREATMENT
Physicians may choose to use therapies that replace antibodies (immunoglobulins) or increase the number of neutrophils (granulocyte–colony stimulating factor (G-CSF)), vaccinations (e.g. HPV), and prophylacticantibiotics to reduce the risk of infections in patients with WHIM syndrome. The dose of G-CSF (e.g., filgrastim) should be individualized, based on each patient’s level of neutropenia. The effectiveness of these treatments, in patients with WHIM syndrome, has not been investigated in controlled trials, presumably because of the low number of study subjects available. However, based on drug trials in patients with other types of immune disorders, it is a recommended practice. In an international review of patient cases, roughly half of patients with WHIM syndrome were given antibiotic prophylaxis. Seventy-two percent of patients were administered granulocyte–colony stimulating factors ([G-CSF], e.g., filgrastim), and 55% were given intravenous immunoglobulin treatments.
Unfortunately, therapy with G-CSF does not help resolve either the lymphopenia or monocytopenia associated with WHIM syndrome and has no effect on HPV -induced warts. Furthermore, G-CSF use can result in severe bone pain and chronic G-CSF use can cause other hematologic conditions. A review of 24 patients with WHIM syndrome in 9 families found that although G-CSF therapy is deemed controversial, it was effective in preventing and treating infections.
Warts are classically reported to be resistant to treatment, may proliferate extensively, and affect the hands or feet, face, arms, or legs. Approximately 20 to 25% of WHIM patients report anogenital condyloma acuminata. Anogenital warts are at particularly high risk of malignant transformation. Indeed, the literature describes multiple cases of cervical and vulvar dysplasia that progressed to invasive genital cancer.
There are currently no approved treatments addressing HPV susceptibility and HPV vaccine response appears impaired with no substantial reduction in the burden of lesions. Standard treatment methods (cauterization, laser therapy) and more aggressive approaches (surgical removal, interferon, cidofovir, Imiquimod) have not proven effective against cutaneous or genital warts.
COMPLICATIONS OF WHIM SYNDROME
Reports underscore the importance of early diagnosis in patients with chronic neutropenia. Immediate long-term treatment strategies, careful monitoring, and timely intervention for complications may control the frequency of bacterial infections and prevent future complications.
Beyond HPV-related malignancies and the threat of recurrent infections, patients with WHIM may be subject to additional long-term complications. For example, recurrent otitis media infection can predispose these patients to hearing loss. Lung damage resulting from frequent infections can cause chronic bronchiectasis or other serious respiratory problems.
A case study from McDermott’s team from the National Institutes of Health discussed the appearance of ocular toxoplasmosis (a protozoan infection) in a 14-year-old patient. In this patient, the infection resulted in permanent blindness in the affected eye.. Additional complications can include neurologic disorders, such as fine and global motor coordination disorders, balance disturbances, or mild limb ataxia.
Importantly, WHIM patients may be at a higher risk of malignancy. A 2019 report from China described a patient with acute myeloid leukemia that developed following Hodgkin’s lymphoma. The French registry reported that five WHIM patients that developed malignancy at median age of 37 years: two HPV-induced vulvar cancers (one lethal), 2 lymphomas (one bone, one skin lymphoma) and one basal cell carcinoma of the 14 patients in the registry. The 40-years rate of malignancy was calculated to be 46% (95% CI 17-88%).
NOVEL TREATMENTS ON THE HORIZON
To date, CXCR4 antagonists (e.g., plerixafor) have shown encouraging results in National Institute of Health (NIH) sponsored clinical trials as a potential treatment for adults with WHIM syndrome. Plerixafor is a subcutaneously injectable pharmaceutical that was approved at a high dose in December 2008 for acute use in patients undergoing autologous bone marrow transplant to treat certain types of hematologic cancers. Plerixafor is not an approved therapy for the treatment of WHIM syndrome. However, the NIH has conducted clinical trials using very low-dose, twice daily subcutaneous injections to demonstrate safety and efficacy in patients with WHIM syndrome. It is unknown if the manufacturer of plerixafor will pursue an approval for use in WHIM syndrome.
Another CXCR4 antagonist, mavorixafor, is a small molecule (supplied as an oral capsule), non-competitive, allosteric antagonist of CXCR4 in a global Phase 3 clinical trial evaluating the safety and efficacy in patients who have been genetically confirmed to have WHIM syndrome. (4WHIM.com)
To date, four WHIM patients who have received allogeneic hematopoietic stem cell transplantation (HSCT) have achieved durable results, no longer receive immunosuppression, and appear to be cured. HSCT in WHIM syndrome is limited by the availability of immunologically matched donors and by the significant short and long-term risks of allotransplantation.
Since the root cause of WHIM syndrome is a mutation in a specific gene (CXCR4), gene editing techniques may provide a promising avenue for research. In one patient with WHIM syndrome, the natural deletion of one copy of the gene reportedly resulted in a cure, with spontaneous and complete remission of warts, sustained correction of neutropenia and monocytopenia, and normalization of bone marrow pathology. In this patient, one copy of the CXCR4 allele was deleted in a hematopoietic stem cell, which was then used to repopulate the patient’s bone marrow. Subsequently, researchers conducted testing in mice and proposed, based on the results of this animal study, that “WHIM allele silencing of patient [hematopoietic stem cells] is a viable gene therapy strategy.”
CLINICAL TRIAL INFORMATION
PRIMARY IMMUNE DEFICIENCY ADVOCACY GROUPS AND NONPROFIT ORGANIZATIONS
A national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.
International Patient Organisation for Primary Immunodeficiencies
An association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency patients worldwide.
Jeffrey Modell Foundation
An international, non-profit, organization dedicated to helping individuals and family members affected by primary immunodeficiency disorders.
RARE DISEASE ORGANIZATIONS
A non-governmental patient-driven alliance of patient organizations representing 724 rare disease patient organizations in 64 countries.
A nonprofit health advocacy organization that engages individuals, families, and communities to transform health. They create ways to make it easier to find or build solutions in health services and research.
A rare disease patient advocacy organization that aims to build awareness, educate the global community and provide critical connections and resources that equip advocates to become activists for their disease.
National Organization for Rare Disorders
A rare disease patient advocacy organization providing a unified voice for the 30 million people who wake up every day to fight the battle with a rare disease, including parents and caregivers.
EveryLife Foundation for Rare Diseases
A rare disease patient advocacy organization dedicated to advancing the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy.
- WHIM syndrome. National Institutes of Health: Genetic and Rare Disease Information Center. December 2019. https://rarediseases.info.nih.gov/diseases/9297/whim-syndrome#).Accessed December 12, 2019.
- Diaz G, Gulino V. WHIM syndrome. June 2004. https://www.orpha.net/data/patho/GB/uk-Whim.pdf. Accessed December 13, 2019.
- Cohen SB, Fenneteau O, Plouvier, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71. doi: 10.1186/1750-1172-7-71
- Dotta L, Notarangelo LD, Moratto D, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol Pract. 2019;7:1568-1577. doi: 10.1016/j.jaip.2019.01.045.
- Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39:532-556. doi: 10.1007/s10875-019-00665-w.
- Wetzler M, Talpaz M, Kleineman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med. 1990;89(5):663-72.
- Beaussant Cohen S, Fenneteau O, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Di 2012, 7:71.
- Aghamohammadi A, Abolhassani H, Puchalka J, et al. Preference of genetic diagnosis of CXCR4 mutation compared with clinical diagnosis of WHIM syndrome. J Clin Immunol. 2017;37:282–6.
- Donadieu J. WHIM syndrome is associated with a high incidence malignancies mainly related to HPV- and EBV- infections. Presented at the 2019 Focused Meeting of the European Society for Immunodeficiencies; Brussels, Belgium; Sept 18-21, 2019.(https://cslide.ctimeetingtech.com/esid19/attendee/person/35
- WHIM syndrome. National Organization for Rare Disorders. 2016. https://rarediseases.org/rare-diseases/whim-syndrome/. Accessed December 12, 2019.
- Heusinkveld LE, Yim E, Yang A. Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency. Expert Opin Orphan Drugs. 2017;5:813-825. doi: 10.1080/21678707.2017.1375403.
- McDermott DH, Pastrana DV, Calvo KR, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380:163-170. doi: 10.1056/NEJMoa1808575.
- Dale DC, Dick E, Kelley M, et al. Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome. Curr Opin Hematol. 2020;27:11-17. doi: 10.1097/MOH.0000000000000554.
- Handisurya A, Schellenbacker C, Reininger B, et al. A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. 2010;28:4837-4841.
- Zhang A, Chen X, Li Z, et al. Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome. Pediatr Blood Cancer. 2019;66:e27951. doi: 10.1002/pbc.27951.
- McDermott DH, Heusinkveld LE, Zein WM, et al. Case report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient. Version 2. F1000Res. 2019 Jan 2 [revised 2019 Jul 17];8:2. doi: 10.12688/f1000research.16825.2.
- Galli J, Pinelli L, Micheletti S, et al. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings. Orphanet J Rare Dis. 2019;14:61. doi: 10.1186/s13023-019-1030-8.
- Mozobil prescribing information. Sanofi-Genzyme. 2019. http://products.sanofi.us/Mozobil/mozobil.html. Accessed December 16, 2019.
- McDermott DH, Gao JL, Murphy PM. Chromothriptic cure of WHIM syndrome: implications for bone marrow transplantation. Rare Diseases. 2015;3:e1073430
- Gao JL, Owusu-Ansah A, Paun A, et al. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice. JCI Insight. 2019 Nov 5. pii: 132140. doi: 10.1172/jci.insight.132140. [Epub ahead of print].
Importance of Advocating
Gene Testing and WHIM Syndrome
This WHIM Learning Page is supported by X4 Pharmaceuticals. This content was developed by CheckRare; the supporter did not influence the final article or editorial themes of this article. For more information on CheckRare’s editorial policy and focus, click here.